Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9253-9260

  Dall'Agata, Marco ^a   Gramenzi, Annagiulia ^a   Biselli, Maurizio ^a   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Direct antiviral agents; Hepatitis C virus; Immunosuppressive agents; Liver transplantation; Peginterferon ribavirin

Indexed keywords

ANTIVIRUS AGENT; DIRECT ANTIVIRAL AGENT; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMBASE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; LIVER TRANSPLANTATION; MEDLINE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REINFECTION; VIRUS REPLICATION; WEB OF SCIENCE; ADVERSE EFFECTS; COMPLICATION; DRUG EFFECTS; HEPACIVIRUS; LIVER CIRRHOSIS; PATHOGENICITY; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84908880331     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9253     Document Type: Article

References (65)

1. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29: 3-18 [PMID: 19235656 DOI: 10.1055/s-0029-1192052]
2. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, Harper AM, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 2013; 13 Suppl 1: 73-102 [PMID: 23237697 DOI: 10.1111/ajt.12021]
3. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004; 17: 363-371 [PMID: 15241083 DOI: 10.1097/01. qco.0000136934.06039.01]
4. Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. Curr Opin Organ Transplant 2005; 10: 81-89 [DOI: 10.1097/01.mot.0000161761.40866.12]
5. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451-455 [PMID: 14960533 DOI: 10.1136/gut.2003.021691]
6. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ, Wiesner RH, Charlton MR, Persing DH. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000; 13: 229-237 [PMID: 10757333 DOI: 10.1038/modpathol. 3880043]
7. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, Burgart L, Wiesner R, Kremers W, Rosen C, Charlton MR. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-1130 [PMID: 11050065 DOI: 10.1053/jhep.2000.19340]
8. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684 [PMID: 10782918 DOI: 10.1016/S0168-8278(00)80231-7]
9. Féray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, Urdea M, Reynes M, Bréchot C, Bismuth H. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-1143 [PMID: 7927244]
10. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, San Juan F, Burgueño MD, Mir J, Berenguer J. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858 [PMID: 11003634 DOI: 10.1053/jhep.2000.17924]
11. Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-678 [PMID: 11690716 DOI: 10.1016/S0168-8278(01)00179-9]
12. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127-143 [PMID: 16723165 DOI: 10.1016/j.jhep.2006.05.001]
13. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl 2003; 9: 1019-1024 [PMID: 14526394 DOI: 10.1053/jlts.2003.50206]
14. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896 [PMID: 11910340 DOI: 10.1053/gast.2002.32418]
15. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, Garcia-Valdecasas JC, Salizzoni M, Moreno GE, Mirza D. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006; 81: 7-14 [PMID: 16421468 DOI: 10.1097/01.tp.0000188619.30677.84]
16. Biselli M, Gramenzi A, Del Gaudio M, Ravaioli M, Vitale G, Gitto S, Grazi GL, Pinna AD, Andreone P, Bernardi M. Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol 2010; 44: 52-57 [PMID: 19581813 DOI: 10.1097/MCG.0b013e3181a390a8]
17. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157 [PMID: 1988336 DOI: 10.1002/hep.1840130122]
18. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynés M, Okamoto H, Bismuth H, Bréchot C. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-1096 [PMID: 7698576 DOI: 10.1016/0016-5085 (95)90207-4]
19. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210 [PMID: 12085366 DOI: 10.1053/jhep.2002.33993]
20. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830 [PMID: 9731579 DOI: 10.1002/hep.510280333]
21. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369 [PMID: 11965581 DOI: 10.1053/jlts.2002.32282]
22. McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis 2000; 2: 166-185 [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x]
23. Davis GL, O'Leary JG. Use of protease inhibitors in liver transplant recipients. Gastroenterol Hepatol (N Y) 2012; 8: 183-184 [PMID: 22675280]
24. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-397 [PMID: 19918980 DOI: 10.1002/hep.23340]
25. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124 [PMID: 15636619 DOI: 10.1111/j.1600-6143.2004.00648.x]
26. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J, Lopez-Talavera JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298 [PMID: 15660392 DOI: 10.1002/hep.20560]
27. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599 [PMID: 16827859 DOI: 10.1111/j.1600-6143.2006.01362.x]
28. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674 [PMID: 15030984 DOI: 10.1016/j.jhep.2003.12.015]
29. Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E, Bonvicini F, Cursaro C, Bernardi M. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006; 38: 27-32 [PMID: 16311084 DOI: 10.1016/j.dld.2005.08.009]
30. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-1076 [PMID: 16622844 DOI: 10.1002/lt.20737]
31. Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, Neuhaus P. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-47 [PMID: 16861940 DOI: 10.1097/01.tp.0000225827.18034.be]
32. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-1108 [PMID: 17377914 DOI: 10.1002/lt.21121]
33. Crespo G, Carrión JA, Coto-Llerena M, Mariño Z, Lens S, Pérez-Del-Pulgar S, García-Retortillo M, Miquel R, Bosch J, Navasa M, Forns X. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol 2013; 48: 762-769 [PMID: 23011083 DOI: 10.1007/s00535-012-0680-2]
34. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465 [PMID: 17196700 DOI: 10.1016/j.jhep.2006.10.017]
35. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEGinterferon and ribavirin. Am J Transplant 2006; 6: 2348-2355 [PMID: 16869810 DOI: 10.1111/j.1600-6143.2006.01470.x]
36. Manos MM, Ho CK, Murphy RC, Shvachko VA. Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patientreported outcomes. Patient 2013; 6: 23-34 [PMID: 23420134 DOI: 10.1007/s40271-013-0005-4]
37. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324 [PMID: 21254179 DOI: 10.1002/hep.24074]
38. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-185, 1577-185, [PMID: 20708617 DOI: 10.1053/j.gastro.2010.07.058]
39. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777 [PMID: 19025933 DOI: 10.1002/lt.21635]
40. Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int 2014; 34 Suppl 1: 46-52 [PMID: 24373078 DOI: 10.1111/liv.12406]
41. Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889. e1 [PMID: 21699786 DOI: 10.1053/j.gastro.2011.05.046]
42. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142: 1340-1350.e1 [PMID: 22537441 DOI: 10.1053/j.gastro.2012.02.015]
43. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441 [PMID: 23669289 DOI: 10.1016/j.jhep.2013.04.035]
44. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700 [PMID: 23696372 DOI: 10.1002/lt.23669]
45. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86 [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018]
46. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-1470 [PMID: 22941516 DOI: 10.1002/lt.23542]
47. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. PLoS One 2013; 8: e80528 [PMID: 24265827 DOI: 10.1371/journal.pone.0080528]
48. Werner CR, Egetemeyr DP, Nadalin S, Königsrainer A, Malek NP, Lauer UM, Berg CP. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol 2014; 52: 27-34 [PMID: 24420796 DOI: 10.1055/s-0033-1356345]
49. Verna EC, Burton JR, O'Leary JG, Lai JC, Saxena V, Dodge JL, Everson GT, Trotter JF, Stravitz RT, Brown RS, Terrault NA, Crush C. A multicenter studt of protease inhibitor-triple therapy in HCV infected liver transplant recipients: report from the CRUSH-C group. J Hepatol 2013; Suppl 1: S10-S11 [DOI: 10.1016/S0168-8278(13)60025-2]
50. Aqel BA, Koning L, Charlton M, Carey EJ, Byrne TJ, Rakela J, Vargas HE. Multicenter preliminary experience utilizing boceprevir with pegylated interferon and ribavirin for the treatment of recurrent hepatitis C genotype 1 after liver transplantation. Hepatology 2012 (Abstract, AASLD Meeting 2012)
51. McCashland TM, Olivera-Martinez MA, Garcia-Saenz De Sicilia M, Mukherjee S, Rochling AF, Schafer DF, Sorrell MF. Early experience with triple drug therapy (telaprevir, pegylated interferon alfa2A and ribavirin) in patients on cyclosporine A for hepatitis C recurrence after liver transplantation. Liver Transpl 2012; 18: S99
52. Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety and tolerability. Am J Transplant 2012; 12 Suppl 3: S147
53. Kwo P, Ghabril M, Lacerda M, Vinayek, Tector AJ, Fridell J, Vianna R. Use of telaprevir plus peg interferon/ribarivin for null responder post OLT with advanced fibrosis/cholestatic hepatitis C. J Hepatol 2012; 56 Suppl 2: S86 [DOI: 10.1016/S0168-8278(12)60215-3]
54. de Oliveira PAP, Shin HJ, Safdar A, Tobias H, Gelb B, Morgan G, Diflo T, Winnick A, Teperman L. Post liver transplant therapy with telaprevir for recurrent hepatitis C. Am J Transplant 2012; 12: 430
55. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-1059 [PMID: 22706796 DOI: 10.1002/lt.23482]
56. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605 [PMID: 23593993 DOI: 10.1111/ajt.12209]
57. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287 [PMID: 18571272 DOI: 10.1016/j.jhep.2008.05.002]
58. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650 [PMID: 12612903 DOI: 10.1053/gast.2003.50095]
59. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57: 974-984 [PMID: 23081753 DOI: 10.1002/hep.26096]
60. Lubbe J. Dermatological side effects. Hot Topics Viral Hep 2008; 9: 29-35
61. Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012; 32 Suppl 1: 32-38 [PMID: 22212569 DOI: 10.1111/j.1478-3231.2011.02707.x]
62. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 2013; 53: 427-449 [PMID: 23140245 DOI: 10.1146/annurev-pharmtox- 011112-140254]
63. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]
64. Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630 [PMID: 22576324 DOI: 10.1002/hep.25831]
65. Coilly A, Furlan V, Roche B, Barau C, Noël C, Bonhomme-Faivre L, Antonini TM, Roque-Afonso AM, Samuel D, Taburet AM, Duclos-Vallée JC. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56: 5728-5734 [PMID: 22908172 DOI: 10.1128/AAC.01151-12]